Lung cancer is the leading cause of death by cancer in North America. A decade ago,
genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase …

Gene fusions have a pivotal role in non-small cell lung cancer (NSCLC) precision medicine.
Several techniques can be used, from fluorescence in situ hybridization and …

Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated
with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit …

Since the discovery of anaplastic lymphoma kinase fusion-positive (ALK+) NSCLC in 2007,
the methods to detect ALK+ NSCLC have evolved and expanded from fluorescence in situ …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Introduction Frequently, patients with locally advanced or metastatic NSCLC are screened
for mutations and fusions. In most laboratories, molecular workup includes a multitude of …

ALK rearranged renal cell carcinoma (ALK-RCC) has recently been included in 2016 WHO
classification as a provisional entity. In this study, we describe 12 ALK-RCCs from 8 …

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer
cases and is the leading cause of cancer-related death. Despite advances in chemotherapy …

Recent changes in lung cancer care, including new approvals in first line and the
introduction of high-throughput molecular technologies in routine testing led us to question …

PURPOSE Gene fusions play a significant role in cancer etiology, making their detection
crucial for accurate diagnosis, prognosis, and determining therapeutic targets. Current …